C-GSZWOrsoBio
energy metabolism, energy homeostasis, first-in-class therapies
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-GSZW
C-GSZWC-GSZWenergy metabolism, energy homeostasis, first-in-class therapies
0-100 chain-logic scale · 15 dimensions · scored on public evidence
OrsoBio states that it is advancing first-in-class therapies to restore energy homeostasis and is developing novel treatments for severe metabolic disorders such as diabetes, severe dyslipidemias, and lipodystrophies. The company says its therapies target central pathways of energy metabolism and reflects a belief that modulating these pathways can improve metabolic disease outcomes.
SourceOrsoBio states that severe metabolic disorders should be treated by targeting fundamental pathways of energy metabolism to restore energy homeostasis. The company presents the view that modulating core metabolic mechanisms can improve insulin sensitivity, plasma lipids, hepatic steatosis, energy expenditure, cardiovascular health, NAD+ biosynthesis, and mitochondrial function across conditions such as obesity, diabetes, dyslipidemias, NASH, lipodystrophies, and liver or kidney dysfunction.
SourceOrsoBio states that severe metabolic disorders can be treated through first-in-class therapies that restore energy homeostasis by targeting central pathways of energy metabolism. The company presents this as a mechanism-driven approach to improve insulin sensitivity, lipid levels, energy expenditure, cardiovascular health, NAD+ biosynthesis, and mitochondrial function across diseases such as type 2 diabetes, severe dyslipidemias, lipodystrophies, and organ dysfunction.
Source